Download PDF
Thromb Haemost 2018; 118(07): 1131-1140
DOI: 10.1055/s-0038-1649484
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention

Dimitrios Alexopoulos
1   2nd Department of Cardiology, Attikon University Hospital, National and Capodistrian University of Athens Medical School, Athens, Greece
,
Iosif Xenogiannis
1   2nd Department of Cardiology, Attikon University Hospital, National and Capodistrian University of Athens Medical School, Athens, Greece
,
Panagiotis Vlachakis
1   2nd Department of Cardiology, Attikon University Hospital, National and Capodistrian University of Athens Medical School, Athens, Greece
,
Udaya Tantry
2   Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, Virginia, United States
,
Paul A. Gurbel
2   Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, Virginia, United States
› Author Affiliations Funding None.
Further Information

Publication History

08 January 2018

23 March 2018

Publication Date:
04 June 2018 (online)

   Permissions and Reprints

Abstract

Platelet activation and aggregation play a pivotal role in thrombotic complications occurring during percutaneous coronary intervention (PCI), and peri-PCI anti-platelet therapy represents a standard of care. High platelet reactivity prior to PCI has been correlated with an increased incidence of peri-procedural myonecrosis. Pre-PCI platelet reactivity predicts post-PCI platelet reactivity and has a prognostic impact on subsequent ischaemic and bleeding events, so as the platelet inhibition measured post-PCI. Many anti-platelet treatment strategies, including aspirin, glycoprotein IIb/IIIa inhibitors, P2Y12 receptor blockers and vorapaxar, are being used in the routine clinical practice to modify platelet reactivity at each stage, e.g. pre-, during and post-PCI. Anti-platelet strategies with a ‘stronger and faster’ pharmacodynamic effect than clopidogrel have been mostly adopted in patients with acute coronary syndromes. However, several issues regarding the anti-platelet treatment such as benefits/risks of anti-platelet therapy pre-treatment and duration, and definite association between speed and potency of various anti-platelet agents and clinical outcomes remain controversial. We believe that a better understanding of peri-PCI platelet reactivity and its relations to outcomes may lead to the development of more effective and safe treatment strategies.

Keywords

coronary angioplasty - anti-platelet treatment - platelet reactivity

Supplementary Material

 

  • References

  • 1 Tantry US, Bonello L, Aradi D. , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
    CrossrefPubMedGoogle Scholar
  • 2 Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol 2011; 57 (10) 1190-1199
    CrossrefPubMedGoogle Scholar
  • 3 Kereiakes DJ, Gurbel PA. Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. JACC Cardiovasc Interv 2008; 1 (02) 111-121
    CrossrefPubMedGoogle Scholar
  • 4 Campo G, Valgimigli M, Gemmati D. , et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48 (11) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 5 Alexopoulos D, Xanthopoulou I, Goudevenos J. Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2014; 113 (12) 2064-2069
    CrossrefPubMedGoogle Scholar
  • 6 Alexopoulos D, Xanthopoulou I, Tsigkas G. , et al. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction. Thromb Res 2013; 131 (04) 333-337
    CrossrefPubMedGoogle Scholar
  • 7 Cuisset T, Frere C, Quilici J. , et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97 (02) 282-287
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Mangiacapra F, Barbato E, Patti G. , et al. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010; 3 (03) 318-323
    CrossrefPubMedGoogle Scholar
  • 9 Legrand V, Cuisset T, Chenu P. , et al. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. EuroIntervention 2014; 10 (02) 204-211
    CrossrefPubMedGoogle Scholar
  • 10 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107 (23) 2908-2913
    CrossrefPubMedGoogle Scholar
  • 11 Frelinger III AL, Michelson AD, Wiviott SD. , et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106 (02) 219-226
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Alexopoulos D, Xanthopoulou I, Davlouros P. , et al. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients. J Thromb Haemost 2013; 11 (02) 381-384
    CrossrefPubMedGoogle Scholar
  • 13 Mayer K, Bernlochner I, Braun S. , et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol 2014; 64 (09) 863-871
    CrossrefPubMedGoogle Scholar
  • 14 Gurbel PA, Bliden KP, Guyer K. , et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46 (10) 1820-1826
    CrossrefPubMedGoogle Scholar
  • 15 Kabbani SS, Watkins MW, Ashikaga T. , et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104 (02) 181-186
    CrossrefPubMedGoogle Scholar
  • 16 Hochholzer W, Trenk D, Bestehorn HP. , et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48 (09) 1742-1750
    CrossrefPubMedGoogle Scholar
  • 17 Breet NJ, van Werkum JW, Bouman HJ. , et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97 (12) 983-990
    CrossrefPubMedGoogle Scholar
  • 18 Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011; 107 (07) 995-1000
    CrossrefPubMedGoogle Scholar
  • 19 Mangiacapra F, Ricottini E, Barbato E. , et al. Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score. Circ Cardiovasc Interv 2015; 8 (05) e002106
    CrossrefPubMedGoogle Scholar
  • 20 Gurbel PA, Serebruany VL, Komjathy SF. , et al. Regional and systemic platelet function is altered by myocardial ischemia-reperfusion. J Thromb Thrombolysis 1995; 1 (02) 187-194
    CrossrefPubMedGoogle Scholar
  • 21 Kang MK, Jeong YH, Yoon SE. , et al. Pre-procedural platelet reactivity after clopidogrel loading in Korean patients undergoing scheduled percutaneous coronary intervention. J Atheroscler Thromb 2010; 17 (11) 1122-1131
    CrossrefPubMedGoogle Scholar
  • 22 Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992; 12 (12) 1475-1487
    CrossrefPubMedGoogle Scholar
  • 23 Serrano Jr CV, Ramires JA, Venturinelli M. , et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997; 29 (06) 1276-1283
    CrossrefPubMedGoogle Scholar
  • 24 Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. ; Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145 (02) 239-247
    CrossrefPubMedGoogle Scholar
  • 25 Chan MY, Weitz JI, Merhi Y, Harrington RA, Becker RC. Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. J Thromb Thrombolysis 2009; 28 (03) 366-380
    CrossrefPubMedGoogle Scholar
  • 26 Janssen PWA, Mol EA, Geene SMC, Barbato E, Ten Berg JM. Does percutaneous coronary stent implantation increase platelet reactivity?. Blood Rev 2017; 31 (05) 271-275
    CrossrefPubMedGoogle Scholar
  • 27 Mangiacapra F, Bartunek J, Bijnens N. , et al. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost 2012; 10 (12) 2452-2461
    CrossrefPubMedGoogle Scholar
  • 28 Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 2009; 123 (06) 874-880
    CrossrefPubMedGoogle Scholar
  • 29 Navarese EP, Schulze V, Andreotti F. , et al. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. JACC Cardiovasc Interv 2015; 8 (1 Pt B): 201-213
    CrossrefPubMedGoogle Scholar
  • 30 Valgimigli M, Frigoli E, Leonardi S. , et al; MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 373 (11) 997-1009
    CrossrefPubMedGoogle Scholar
  • 31 Laine M, Frere C, Cuisset T. , et al. Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. Int J Cardiol 2016; 220: 496-500
    CrossrefPubMedGoogle Scholar
  • 32 Frere C, Laine M, Lemesle G. , et al. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. Platelets 2017; DOI: 10.1080/09537104.2017.1384541.
    CrossrefPubMedGoogle Scholar
  • 33 Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 2004; 15 (02) 95-99
    CrossrefPubMedGoogle Scholar
  • 34 Kaikita K, Ono T, Iwashita S. , et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2014; 21 (01) 64-76
    PubMedGoogle Scholar
  • 35 Heestermans AA, van Werkum JW, Zwart B. , et al. Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. J Thromb Haemost 2010; 8 (11) 2385-2393
    CrossrefPubMedGoogle Scholar
  • 36 Sibbing D, Bernlochner I, Schulz S. , et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol 2012; 60 (05) 369-377
    CrossrefPubMedGoogle Scholar
  • 37 Price MJ, Berger PB, Teirstein PS. , et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305 (11) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 38 Trenk D, Stone GW, Gawaz M. , et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59 (24) 2159-2164
    CrossrefPubMedGoogle Scholar
  • 39 Collet JP, Cuisset T, Rangé G. , et al; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367 (22) 2100-2109
    CrossrefPubMedGoogle Scholar
  • 40 Cayla G, Cuisset T, Silvain J. , et al; ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388 (10055): 2015-2022
    CrossrefPubMedGoogle Scholar
  • 41 Parodi G, Marcucci R, Valenti R. , et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306 (11) 1215-1223
    CrossrefPubMedGoogle Scholar
  • 42 Stone GW, Witzenbichler B, Weisz G. , et al; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382 (9892): 614-623
    CrossrefPubMedGoogle Scholar
  • 43 Bömicke T, Valina CM, Stratz C, Amann M, Neumann FJ, Hochholzer W. On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. Thromb Haemost 2017; 117 (08) 1644-1650
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Park Y, Tantry US, Koh J-S. , et al. Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: the REMODELING Trial. Thromb Haemost 2017; 117 (05) 911-922
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Tada T, Byrne RA, Simunovic I. , et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013; 6 (12) 1267-1274
    CrossrefPubMedGoogle Scholar
  • 46 Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56 (04) 317-318
    CrossrefPubMedGoogle Scholar
  • 47 Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50 (19) 1822-1834
    CrossrefPubMedGoogle Scholar
  • 48 Freynhofer MK, Iliev L, Bruno V. , et al. Platelet turnover predicts outcome after coronary intervention. Thromb Haemost 2017; 117 (05) 923-933
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Kenaan M, Seth M, Aronow HD, Wohns D, Share D, Gurm HS. ; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. J Am Coll Cardiol 2013; 62 (22) 2083-2089
    CrossrefPubMedGoogle Scholar
  • 50 Basili S, Tanzilli G, Raparelli V. , et al. Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. Circ Cardiovasc Interv 2014; 7 (04) 577-584
    CrossrefPubMedGoogle Scholar
  • 51 Nagatsuka K, Miyata S, Kada A. , et al. Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. Thromb Haemost 2016; 116 (02) 356-368
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Ellis SG, Tendera M, de Belder MA. , et al; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358 (21) 2205-2217
    CrossrefPubMedGoogle Scholar
  • 53 Ohlmann P, Reydel P, Jacquemin L. , et al. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv 2012; 5 (01) 69-76 , S1
    CrossrefPubMedGoogle Scholar
  • 54 Bellemain-Appaix A, O'Connor SA, Silvain J. , et al; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308 (23) 2507-2516
    CrossrefPubMedGoogle Scholar
  • 55 Montalescot G, Collet JP, Ecollan P. , et al; ACCOAST Investigators. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol 2014; 64 (24) 2563-2571
    CrossrefPubMedGoogle Scholar
  • 56 Montalescot G, van 't Hof AW, Lapostolle F. , et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedGoogle Scholar
  • 57 Silvain J, Storey RF, Cayla G. , et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116 (02) 369-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Alexopoulos D, Moulias A, Kanakakis I, Xanthopoulou I. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: ready for prime time?. Int J Cardiol 2015; 194: 41-43
    CrossrefPubMedGoogle Scholar
  • 59 Fan W, Plent S, Prats J, Deliargyris EN. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 2016; 117 (09) 1439-1443
    CrossrefPubMedGoogle Scholar
  • 60 Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005; 111 (09) 1153-1159
    CrossrefPubMedGoogle Scholar
  • 61 Kastrati A, Mehilli J, Neumann FJ. , et al; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295 (13) 1531-1538
    CrossrefPubMedGoogle Scholar
  • 62 Hochholzer W, Amann M, Titov A. , et al. Randomized comparison of different thienopyridine loading strategies in patients undergoing elective coronary intervention: the ExcelsiorLOAD Trial. JACC Cardiovasc Interv 2016; 9 (03) 219-227
    CrossrefPubMedGoogle Scholar
  • 63 Angiolillo DJ, Franchi F, Waksman R. , et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI. J Am Coll Cardiol 2016; 67 (06) 603-613
    PubMedGoogle Scholar
  • 64 Alexopoulos D, Xanthopoulou I, Gkizas V. , et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5 (06) 797-804
    CrossrefPubMedGoogle Scholar
  • 65 Bhatt DL, Stone GW, Mahaffey KW. , et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368 (14) 1303-1313
    CrossrefPubMedGoogle Scholar
  • 66 Généreux P, Stone GW, Harrington RA. , et al; CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63 (07) 619-629
    CrossrefPubMedGoogle Scholar
  • 67 Mohammad MA, Andell P, Koul S. , et al. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets 2017; 28 (04) 414-416
    CrossrefPubMedGoogle Scholar
  • 68 Droppa M, Spahn P, Takhgiriev K. , et al. Periprocedural platelet inhibition with cangrelor in P2Y12-inhibitor naïve patients with acute coronary syndromes - a matched-control pharmacodynamic comparison in real-world patients. Int J Cardiol 2016; 223: 848-851
    CrossrefPubMedGoogle Scholar
  • 69 Becker RC, Moliterno DJ, Jennings LK. , et al; TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373 (9667): 919-928
    CrossrefPubMedGoogle Scholar
  • 70 Tricoci P, Huang Z, Held C. , et al; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366 (01) 20-33
    CrossrefPubMedGoogle Scholar
  • 71 Brar SS, ten Berg J, Marcucci R. , et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58 (19) 1945-1954
    CrossrefPubMedGoogle Scholar
  • 72 Bonello L, Pansieri M, Mancini J. , et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58 (05) 467-473
    CrossrefPubMedGoogle Scholar
  • 73 Bonello L, Mancini J, Pansieri M. , et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10 (10) 1999-2005
    CrossrefPubMedGoogle Scholar
  • 74 Antman EM, Wiviott SD, Murphy SA. , et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51 (21) 2028-2033
    CrossrefPubMedGoogle Scholar
  • 75 Cannon CP, Harrington RA, James S. , et al; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375 (9711): 283-293
    CrossrefPubMedGoogle Scholar
  • 76 Zafar MU, Baber U, Smith DA. , et al. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost 2017; 117 (10) 1981-1988
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Aradi D, Kirtane A, Bonello L. , et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36 (27) 1762-1771
    CrossrefPubMedGoogle Scholar
  • 78 Van't Hof AW, Ten Berg J, Heestermans T. , et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372 (9638): 537-546
    CrossrefPubMedGoogle Scholar
  • 79 Cuisset T, Frere C, Quilici J. , et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008; 1 (06) 649-653
    CrossrefPubMedGoogle Scholar
  • 80 Valgimigli M, Campo G, de Cesare N. , et al; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119 (25) 3215-3222
    CrossrefPubMedGoogle Scholar
  • 81 Levine GN, Bates ER, Blankenship JC. , et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58 (24) e44-e122
    CrossrefPubMedGoogle Scholar
  • 82 Valgimigli M, Bueno H, Byrne RA. , et al; ESC Scientific Document Group. ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
    CrossrefPubMedGoogle Scholar
  • 83 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
    CrossrefPubMedGoogle Scholar
  • 84 Steg PG, Harrington RA, Emanuelsson H. , et al; PLATO Study Group. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128 (10) 1055-1065
    CrossrefPubMedGoogle Scholar
  • 85 Velders MA, Abtan J, Angiolillo DJ. , et al; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 2016; 102 (08) 617-625
    CrossrefPubMedGoogle Scholar